Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Mar;16(1):50-5.
doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12.

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer

C J Paller  1 , X Ye, P J Wozniak, B K Gillespie, P R Sieber, R H Greengold, B R Stockton, B L Hertzman, M D Efros, R P Roper, H R Liker, M A Carducci
Affiliations
Clinical Trial

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer

C J Paller et al. Prostate Cancer Prostatic Dis. 2013 Mar.

Abstract

Background: Pomegranate juice has been associated with PSA doubling time (PSADT) elongation in a single-arm phase II trial. This study assesses biological activity of two doses of pomegranate extract (POMx) in men with recurrent prostate cancer, using changes in PSADT as the primary outcome.

Methods: This randomized, multi-center, double-blind phase II, dose-exploring trial randomized men with a rising PSA and without metastases to receive 1 or 3 g of POMx, stratified by baseline PSADT and Gleason score. Patients (104) were enrolled and treated for up to 18 months. The intent-to-treat (ITT) population was 96% white, with median age 74.5 years and median Gleason score 7. This study was designed to detect a 6-month on-study increase in PSADT from baseline in each arm.

Results: Overall, median PSADT in the ITT population lengthened from 11.9 months at baseline to 18.5 months after treatment (P < 0.001). PSADT lengthened in the low-dose group from 11.9 to 18.8 months and 12.2 to 17.5 months in the high-dose group, with no significant difference between dose groups (P = 0.554). PSADT increases >100% of baseline were observed in 43% of patients. Declining PSA levels were observed in 13 patients (13%). In all, 42% of patients discontinued treatment before meeting the protocol-definition of PSA progression, or 18 months, primarily due to a rising PSA. No significant changes occurred in testosterone. Although no clinically significant toxicities were seen, diarrhea was seen in 1.9% and 13.5% of patients in the 1- and 3-g dose groups, respectively.

Conclusions: POMx treatment was associated with ≥ 6 month increases in PSADT in both treatment arms without adverse effects. The significance of this on-study slowing of PSADT remains unclear, reinforcing the need for placebo-controlled studies in this patient population.

Trial registration: ClinicalTrials.gov NCT01220817.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The corresponding author, Michael Carducci, received $1500 in 2007 from POM Wonderful, LLC, for participating in a discussion of future trials. Harley Liker and Patricia Wozniak are consultants to POM Wonderful, LLC, and Brad Gillespie was, until 2011, the vice president of POM Wonderful. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PSADT percentage change from baseline for each patient in the 1-POMx and 3-POMx treatment groups. (Notes: (1) Patients with negative baseline PSADT were excluded, (2) Patients with negative post-baseline PSADT were assigned the largest observed post-baseline PSADT and (3) Six 1-POMx and nine 3-POMx subjects had PSADT percentage change from baseline >1000%). POMx, pomegranate extract; PSADT, PSA doubling time.
Figure 2
Figure 2
Number of subjects in each post-baseline PSA doubling time (PSADT) range grouped by baseline PSADT range.
See this image and copyright information in PMC

References

    1. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med. 2010;170:1390–1395. - PubMed
    1. Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol. 1999;162:1337–1340. - PubMed
    1. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439. - PubMed
    1. Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int. 2010;108:378–385. - PMC - PubMed
    1. Arlen PM, Bianco F, Dahut WL, D’Amico A, Figg WD, Freedland SJ, et al. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol. 2008;179:2181–2185. discussion 2185–2186. - PMC - PubMed

Publication types

Associated data